Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1036

1.

Ziprasidone in Black patients with schizophrenia: analysis of four short-term, double-blind studies.

Lawson WB, Herman BK, Loebel A, Lazariciu I, Malik M.

CNS Spectr. 2009 Sep;14(9):478-86.

PMID:
19890230
2.

An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.

Goff DC, Posever T, Herz L, Simmons J, Kletti N, Lapierre K, Wilner KD, Law CG, Ko GN.

J Clin Psychopharmacol. 1998 Aug;18(4):296-304.

PMID:
9690695
3.
4.

Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.

Olié JP, Spina E, Murray S, Yang R.

Int Clin Psychopharmacol. 2006 May;21(3):143-51.

PMID:
16528136
5.

Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studies.

Keck PE Jr, Reeves KR, Harrigan EP; Ziprasidone Study Group.

J Clin Psychopharmacol. 2001 Feb;21(1):27-35.

PMID:
11199944
6.

Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.

Citrome L, Meng X, Hochfeld M, Stahl SM.

Hum Psychopharmacol. 2012 Jan;27(1):24-32. doi: 10.1002/hup.1254. Epub 2011 Dec 7.

PMID:
22161738
7.

Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.

Ratner Y, Gibel A, Yorkov V, Ritsner MS.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Oct 1;31(7):1401-9. Epub 2007 Jun 21.

PMID:
17669574
8.

Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia.

Kane JM, Khanna S, Rajadhyaksha S, Giller E.

Int Clin Psychopharmacol. 2006 Jan;21(1):21-8.

PMID:
16317313
9.

A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia.

Hirsch SR, Kissling W, Bäuml J, Power A, O'Connor R.

J Clin Psychiatry. 2002 Jun;63(6):516-23.

PMID:
12088164
10.

Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial.

Potkin SG, Keck PE Jr, Segal S, Ice K, English P.

J Clin Psychopharmacol. 2005 Aug;25(4):301-10.

PMID:
16012271
11.

Long-term improvement in efficacy and safety after switching to ziprasidone in stable outpatients with schizophrenia.

Simpson GM, O'Gorman CJ, Loebel A, Yang R.

CNS Spectr. 2008 Oct;13(10):898-905.

PMID:
18955945
12.

Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.

Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD.

J Clin Psychopharmacol. 2008 Apr;28(2 Suppl 1):S20-8. doi: 10.1097/JCP.0b013e318169d4ce.

PMID:
18334909
13.
14.

Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study.

Casey DE, Sands EE, Heisterberg J, Yang HM.

Psychopharmacology (Berl). 2008 Oct;200(3):317-31. doi: 10.1007/s00213-008-1207-7. Epub 2008 Jul 4.

PMID:
18597078
15.

Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: results of a multi-centre observational trial.

Kudla D, Lambert M, Domin S, Kasper S, Naber D.

Eur Psychiatry. 2007 Apr;22(3):195-202. Epub 2006 Nov 29.

PMID:
17140769
16.

Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial.

Daniel DG, Potkin SG, Reeves KR, Swift RH, Harrigan EP.

Psychopharmacology (Berl). 2001 May;155(2):128-34.

PMID:
11401000
17.

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW.

J Clin Psychiatry. 2002 Sep;63(9):763-71.

PMID:
12363115
18.
19.

The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study.

Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y.

CNS Drugs. 2009;23(7):615-25. doi: 10.2165/00023210-200923070-00006.

PMID:
19552488
20.

Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial.

Keck P Jr, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Morrissey MR.

Psychopharmacology (Berl). 1998 Nov;140(2):173-84.

PMID:
9860108

Supplemental Content

Support Center